WebJul 1, 2008 · ORCIDs linked to this article. Raoul J, 0000-0001-6305-8953, Institut de cancérologie de l'Ouest, Saint Herblain Borbath I, 0000-0001-7598-214X, Cliniques Universitaires Saint-Luc Greten T, 0000-0002-0806-2535, National Institutes of Health MAZZAFERRO VM, 0000-0002-4013-8085, Fondazione IRCCS Istituto Nazionale dei … WebAug 17, 2024 · The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Contributions A.H., …
Efficacy of lenvatinib for unresectable hepatocellular
WebFeb 1, 2024 · RELPEC and HCC48. 機関名/Institute (機関選択不可の場合) 日本語 RELPEC (多施設共同研究グループ) HCC 48 ... WebAtezolizumab + Bevacizumab for Hepatocellular Carcinoma. Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death. 1 Although early-stage disease may be ... management of pediatric hyperglycemia
Prognostic factor of lenvatinib for unresectable hepatocellular ...
WebFeb 1, 2024 · 切除不能肝細胞癌に対する全身化学療法の治療効果の検討の詳細情報です。進捗状況,試験名,対象疾患名,実施都道府県,お問い合わせ先などの情報を提供しています。 WebJul 15, 2024 · On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Oncology, … WebOct 29, 2024 · On behalf of the Real‐life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Conflict of interest: The authors declare no conflict of interest. Financial support: There is no grant or other financial support for this study. management of patients with neurologic trauma